Guides
Pharmacovigilance Aims and Objectives: Where to Start AI in 2027
Drawing on the Duaer documentation site, this article explains how pharmacovigilance teams can find the right starting point for AI around 2027. Align with core safety objectives first, rank use cases by value and difficulty, then choose a controllable, verifiable first pilot.
Start from Objectives, Not Tools
Pharmacovigilance exists to detect, assess, understand, and prevent adverse reactions to medicines. In principle, its purpose is clear: protect patients, keep the benefit-risk picture of a product up to date, and get evidence to regulators and prescribers in good time. In practice, safety teams are often overwhelmed by case intake, duplicate reports, free-text narratives from call centers and literature, and signal evaluations that never seem to end. That gap is why more pharmaceutical companies are asking where AI can help without weakening the pharmacovigilance objectives it is meant to serve.
Pharmacovigilance systems usually revolve around a few recurring objectives: identifying new safety signals early; processing individual case safety reports (ICSRs) accurately and on time; producing periodic benefit-risk reports; assessing whether risk minimization measures actually work; and ensuring that every decision can withstand audit. Companies and jurisdictions phrase these differently, but the underlying logic is the same.
This matters because many AI projects begin with a capability, such as summarization or classification, and then go looking for a problem to fit. A more sensible order is to first define which objective is under pressure. If the bottleneck is delayed case processing, the use case belongs in case intake. If the gap is literature coverage, it belongs in literature screening. A use case that cannot name the objective it serves is a demonstration, not a pilot.
Understand the Typical Scenarios Before Ranking
Across most safety functions, AI tends to appear in the following recurring scenarios:
**Case intake and triage.** Classifying reports from spontaneous sources, literature, and call centers, and routing them to the correct processing queue.
**Duplicate detection.** Matching reports from different sources that describe the same patient and the same event. Small differences in names, dates, and wording often create a lot of noise.
**Narrative information extraction.** Pulling drug, event, date, outcome, and reporter information from unstructured text into structured fields for human review.
**Literature screening.** Scanning publications for content that may contain safety information relevant to a product.
**Signal detection support.** Flagging unusual patterns for safety scientists to evaluate. The output is a lead for judgment, not a conclusion.
**Drafting.** Preparing first drafts of periodic report or assessment sections, to be signed off by qualified reviewers.
Each scenario carries a different level of regulatory exposure, so these cannot be treated as interchangeable.
Rank by Value and Difficulty, and Treat Regulatory Exposure as a Separate Lens
It is useful to score each candidate scenario on two dimensions. The value dimension covers workload volume, cycle time, and the cost of backlog. The difficulty dimension covers data quality, validation burden, the intensity of required human review, and how tightly the work is coupled to the safety database. For a practical scoring approach, the thinking in Enterprise AI Use Case Prioritization applies equally to regulated work.
In most organizations, duplicate detection and literature screening score high on value and only moderate on difficulty. They involve large volumes of repetitive work and can be checked against historical answers. Automated causality assessment may look attractive, but it scores high on both difficulty and regulatory exposure, so it should not be the lead act in a first pilot. Signal detection is valuable, but it depends on mature data, stable definitions, and clear governance, and it is usually better suited to a second phase.
A practical rule: if an error could directly change a medical or regulatory conclusion without a human check, that use case is not suitable as a first pilot, however high its value score.
Choose a First Pilot for Controllability, Not Ambition
A suitable first pilot should have five characteristics. First, it has a measurable baseline, such as current cycle time, backlog days, or duplicate rate. Second, its data scope is bounded and well understood. Third, when the AI makes a mistake, a human can catch it before it reaches a decision. Fourth, the safety function has a clear owner, not just the IT department. Fifth, its output can be compared against the current manual process using the same historical sample.
For most teams, duplicate flagging or literature screening meets these requirements. Both remove repetitive sorting work while keeping final decisions with people. Before choosing a vendor or platform, lock down the use case first. The approach in Choosing Your First AI Scenario for Pharma Companies applies here as well: once the use case is clear, vendor comparisons become far more objective.
Make Validation Central to the Plan and Measure Results Against Objectives
Validation is where many pilots quietly fail. Build a test set from past cases, making sure the correct conclusion for each case is known, and include some difficult examples. Then measure what really matters. Recall for relevant or serious cases should be the most important metric, because missing a serious case costs far more than sending an extra item for review. Precision affects workload, and the reviewer override rate shows whether people trust the system's output.
Every run should record the model version, prompts, and configuration. Any change requires revalidation. If the pilot involves processes under GxP control, bring in quality assurance at the very beginning. Documentation added after the pilot ends is slow to produce and often forces the project to start over.
For measurement, track cycle time from receipt to completion, the length of backlog, duplicate-detection precision and recall, review minutes per case, and audit findings related to the process. Avoid vanity metrics such as how many reports the AI has 'processed.' If recall drops, or if reviewers spend more time correcting output than the system saves, then high throughput means nothing.
Review these numbers on a fixed schedule and compare them with the original objectives. If a pilot improves speed but weakens completeness, it has not achieved the purpose of pharmacovigilance, however good the dashboard looks.
Do This One Thing This Week
Pull case volume data for the past three months and write down the three steps where cases wait the longest. For each step, record whether the work is repetitive, whether a historical sample with known answers exists, and who on the safety team will be accountable for the results. Then score the candidates on a simple value-versus-difficulty grid. The item that scores highest and has usable historical samples is the candidate for the first pilot. Do not rush to choose a tool before completing this step.
If your team wants a structured method for moving from this checklist to a working pilot, you can sign up for a Duaer trial and use it to build the scoring and validation workflow. Start with one use case and one measurable baseline, and let the results decide whether to expand.
If you tell us your specific scenario, we can prepare a written implementation roadmap for it.
https://api.duaer.com/form/c59a907a-3697-4edf-a04d-3ea0fb72fdc8
Ultimately, pharmacovigilance is about protecting patients through stable, verifiable judgment. AI earns a place in this work only when it shortens the path to that judgment without removing the human oversight that makes the judgment trustworthy.
Questions
In pharmacovigilance, which problem should a company tackle with AI first?
Usually start where the pressure on objectives is most visible, the work is repetitive, and results can be checked against historical samples, such as duplicate detection or literature screening. These scenarios offer high value with moderate difficulty and keep human control over final decisions. Scenarios that directly affect medical or regulatory conclusions, such as automated causality assessment, are not suitable as a first pilot.
How should an AI pilot in pharmacovigilance be validated?
Build a test set from historical cases with known correct conclusions, and include some difficult examples. Focus on recall for relevant or serious cases, and also watch precision, the reviewer override rate, and review time per case. Record the model version, prompts, and configuration for every run, revalidate after any change, and involve quality assurance early.
How can you tell whether an AI pilot truly meets pharmacovigilance objectives?
Do not judge it only by how many reports the AI has processed. Track cycle time, backlog duration, duplicate-detection precision and recall, review time, and related audit findings, and check them regularly against the original business objectives. If speed improves at the cost of completeness, the pilot has missed the core purpose of pharmacovigilance, even if the metrics look good.